inMMyCAR

A Phase 1 Study to Evaluate the Safety of KLN-1010, a Novel, In Vivo Gene Therapy to Generate Anti-B Cell Maturation Antigen (Anti-BCMA) Chimeric Antigen Receptor-T Cells (CAR-T) in Patients With Relapsed and Refractory Multiple Myeloma

Near Add Your Location

Sorting 13 by

Memorial Sloan Kettering Cancer Center
New York, NY
  • Not yet accepting
  • Show Principal Investigator
Stanford University Cancer Institute (Palo Alto)
Stanford, CA
  • Accepting patients
  • Show Principal Investigator
Moffitt Cancer Center
Magnolia Campus
Tampa, FL
  • Not yet accepting
  • Show Principal Investigator
John Theurer Cancer Center at Hackensack University Medical Center 
Hackensack Meridian Health
Hackensack, NJ
  • Not yet accepting
  • Show Principal Investigator
Massachusetts General Hospital
Boston, MA
  • Not yet accepting
  • Show Principal Investigator
Colorado Blood Cancer Institute
Sarah Cannon at Presbyterian/St. Luke's Medical Center (HealthONE)
Denver, CO
  • Not yet accepting
  • Show Principal Investigator
Sarah Cannon Research Institute
TriStar Centennial Medical Center
Nashville, TN
  • Not yet accepting
  • Show Principal Investigator
Providence Oncology and Hematology - Eastside
Providence Cancer Institute Franz Clinic
Portland, OR
  • Accepting patients
  • Show Principal Investigator
Tennessee Oncology - Hayes
Nashville, TN
  • Not yet accepting
  • Show Principal Investigator
UCSF Helen Diller Comprehensive Cancer Center
University of California San Francisco
San Francisco, CA
  • Not yet accepting
  • Show Principal Investigator

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.